Investor Presentaiton
US Business - Significant Ramp-up in Sales.
Key Milestones in US
SUN
PHARMA
Entry in US through Caraco acquisition
Acquired Taro Pharma - Entry into US
dermatology market
Sales in Rs billion
FY98
10 year CAGR 20%
137
138
FY10
135
FY13
• Acquired DUSA - Entry in branded
specialty market
FY13
• Acquired URL's generic business
98
.
FY14
Acquired Pharmalucence -access to
sterile injectable capacity
87
35
23
14
15
11
62
32
© Sun Pharmaceutical Industries Limited. All Rights Reserved.
FY16
FY17
FY18
.
• Acquired InSite Vision - Strengthen
ophthalmic portfolio
• Tildrakizumab filing in US &
Europe market
• Acquired Ocular Technologies
giving access to OTX-101, a
product for treating dry eyes.
• Launched BromSite in US
• Acquired Odomzo-branded
oncology product from Novartis
Launched Odomzo in US
Settlement of Patent Litigation for
Generic LinzessⓇ in US
• US FDA approval for Ilumya
18View entire presentation